GRCE

Grace Therapeutics, Inc.

Grace Therapeutics, Inc. (GRCE) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (C+); its weakest is Growth (C-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C+
Factor Score 2.5 / 5.0
Growth
C-
Factor Score 2.1 / 5.0
Profitability
C+
Factor Score 2.7 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -4.1
EV / EBITDA -2.4
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -10.1%
Price Return 12M -37.8%
Catalyst Signal 0.00
Market Cap $39.0M
TTM Revenue N/A
Price / Sales N/A
ROE -36.2%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-12 C+ (2.5) C- (2.1) C+ (2.7) C+ (2.5) C+ (2.6) C (2.5)
2026-11-05 C+ (2.5) C- (2.1) C+ (2.7) C (2.4) C+ (2.7) C (2.5)
2026-10-29 C+ (2.5) C- (2.0) C+ (2.7) C+ (2.6) C+ (2.7) C+ (2.5)
2026-10-22 C+ (2.5) C- (2.0) C+ (2.7) D+ (1.7) C+ (2.6) C (2.3)
2026-10-15 C+ (2.5) C- (2.0) C+ (2.7) D+ (1.7) C+ (2.6) C (2.3)
Page 1 of 4